In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NASS Looks To Lead Discussion In Spine Reimbursement

Executive Summary

The North American Spine Society is taking what might be an unprecedented step by medical society to help surgeons in their struggles with insurers. It has set out to write its own set of coverage guidelines, which would advise insurers – and surgeons – which spinal procedures payors should cover. NASS established a multidisciplinary 25-person task force to draw up the coverage guidelines. Eventually, the task force hopes to have compiled a book of guidelines advising insurers when a procedure should or shouldn’t be covered.

You may also be interested in...

Sober NASS Reflects Challenges Facing Spine Industry

This years’ gathering of the North American Spine Society (NASS) carried a muted tone that befits a stagnant or shrinking industry. Surgeons in NASS’ leadership spoke to the minimal growth in their own reimbursements and their concerns over how changes in the health care sector will impact the specialty going forward.

Vertebral Compression Fracture Treatments Under Pressure

A decade ago, the treatment of vertebral compression fractures (VCF) represented one of the fastest - and most innovative - segments of a spine industry that was set to explode. The two principal procedures - vertebroplasty and its distant cousin kyphoplasty - presented surgeons and interventionalists with a minimally invasive option to stop pain and, in the case of kyphoplasty, restore the shape and form to a broken vertebra. Now, two studies published in The New England Journal of Medicine suggesting that vertebroplasty procedures were no more effective in relieving pain than a placebo treatment have put pressure on VCF companies and doctors, who are facing pushback on reimbursement and some skepticism from even their own specialists.

Keeping Track: Tumor-Agnostic Approval For Novartis; Submissions From Krystal, Menarini, And Astellas

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts